Neutralizing Monoclonal Antibodies to Botulinum neurotoxin A
Description of Invention:
Available for licensing from the NIH are two chimpanzee-derived monoclonal antibodies (mAbs) against botulinum neurotoxin type A (BoNT/A). These mAbs can be developed for prevention, therapy, or diagnosis of BoNT/A. Use of this technology represents a significant improvement over the existing therapy of supportive care and treatment with equine antitoxin polyclonal antibodies.
Potential Area of Application:
Emergency prophylaxis against BoNT/A outbreak (natural or biodefense-related)
Therapeutic against BoNT/A
Rapid diagnosis of BoNT/A
Therapeutic against overdosage of BoNT/A as used in clinical treatments
Main Advantage of Invention:
No anticipated side effects compared to currently utilized equine antitoxin polyclonal antibodies
Monoclonal instead of polyclonal
Inventors:
Robert H. Purcell et al. (NIAID)
Patent Status:
DHHS Reference No. E-180-2006/0 -- Research Tool
Licensing Status: Available for non-exclusive licensing.
For Additional Information Please Contact: Susan Ano Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5515
Email: anos@mail.nih.gov
Fax: (301) 402-0220
